Synova Capital’ Investment In Preventx


Osborne Clarke has advised Synova Capital on its significant minority growth investment into Preventx.

Synova will support Preventx and its founders Neil Cooper and Tim Alston to deliver an ambitious growth plan built upon the Business’s excellent reputation, unique integrated technology platform and the supportive dynamics of the growing self-sampling diagnostics market.

Preventx was founded in 2008, when Neil and Tim saw the opportunity to deliver both tangible cost savings to Local Authorities and an improved end user experience by shifting sexual health testing out of the traditional clinic setting. Since then, the Business has grown rapidly, driven by the recognition of health commissioners that online-led, self-sample testing is a cost-effective way to deal with rising patient demand. Preventx currently provides services to more than a third of all Local Authorities in England.

Synova Capital is a private equity firm specialising in investments in UK and Irish growth companies.

Osborne Clarke Partner Alisdair Livingstone (Picture), Associate Director Chris Yeo, Senior Associate James Taylor and Associate Bethany Shingfield advised Synova.

Involved fees earner: Alisdair Livingstone – Osborne Clarke; Bethany Shingfield – Osborne Clarke; James Taylor – Osborne Clarke; Chris Yeo – Osborne Clarke;

Law Firms: Osborne Clarke;

Clients: Synova Capital LLP;